BidaskClub upgraded shares of Adaptimmune Therapeutics (NASDAQ:ADAP) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning.
Several other research analysts also recently weighed in on ADAP. Leerink Swann restated an outperform rating on shares of Adaptimmune Therapeutics in a research report on Thursday, March 15th. ValuEngine upgraded shares of Adaptimmune Therapeutics from a sell rating to a hold rating in a research report on Monday, April 2nd. Finally, Zacks Investment Research downgraded shares of Adaptimmune Therapeutics from a hold rating to a sell rating in a research report on Monday, March 19th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $11.58.
ADAP stock opened at $12.11 on Tuesday. Adaptimmune Therapeutics has a 52-week low of $4.28 and a 52-week high of $13.41. The stock has a market cap of $1,160.82, a PE ratio of -15.14 and a beta of 1.19.
Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its earnings results on Thursday, March 15th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.04). Adaptimmune Therapeutics had a negative return on equity of 32.26% and a negative net margin of 185.39%. The firm had revenue of $4.27 million for the quarter, compared to analysts’ expectations of $9.38 million. research analysts predict that Adaptimmune Therapeutics will post -0.82 earnings per share for the current year.
In related news, major shareholder Ravi Viswanathan purchased 104,844 shares of Adaptimmune Therapeutics stock in a transaction that occurred on Wednesday, March 21st. The stock was purchased at an average price of $1.81 per share, for a total transaction of $189,767.64. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Orbimed Advisors Llc sold 1,048,067 shares of the company’s stock in a transaction dated Thursday, March 29th. The stock was sold at an average price of $11.50, for a total transaction of $12,052,770.50. The disclosure for this sale can be found here. In the last 90 days, insiders have purchased 9,385,254 shares of company stock valued at $17,966,655. Insiders own 24.45% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ADAP. Millennium Management LLC raised its holdings in Adaptimmune Therapeutics by 36.5% in the 4th quarter. Millennium Management LLC now owns 805,595 shares of the biotechnology company’s stock valued at $5,381,000 after acquiring an additional 215,439 shares during the last quarter. BlackRock Inc. raised its holdings in Adaptimmune Therapeutics by 43,632.6% in the 4th quarter. BlackRock Inc. now owns 787,187 shares of the biotechnology company’s stock valued at $5,258,000 after acquiring an additional 785,387 shares during the last quarter. Artal Group S.A. raised its holdings in Adaptimmune Therapeutics by 40.0% in the 4th quarter. Artal Group S.A. now owns 700,000 shares of the biotechnology company’s stock valued at $4,676,000 after acquiring an additional 200,000 shares during the last quarter. Alps Advisors Inc. raised its holdings in Adaptimmune Therapeutics by 12.7% in the 4th quarter. Alps Advisors Inc. now owns 103,816 shares of the biotechnology company’s stock valued at $693,000 after acquiring an additional 11,716 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in Adaptimmune Therapeutics by 76.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 87,392 shares of the biotechnology company’s stock valued at $584,000 after acquiring an additional 37,792 shares during the last quarter. Hedge funds and other institutional investors own 55.50% of the company’s stock.
TRADEMARK VIOLATION WARNING: This news story was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://ledgergazette.com/2018/04/20/adaptimmune-therapeutics-adap-upgraded-at-bidaskclub.html.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. Its platform enables to identify cancer targets; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.